Xspray Pharma Signs First Licensing Deal, Eyes Dasynoc Launch

Xspray Pharma signed a deal with Handa Therapeutics that will give it up to double-digit royalties on Handa's net profits, marking the company's first out-licensing arrangement from its patent portfolio.The company's primary plan is still to use its unique  advanced technology called HyNap  to create and market better PKI medications. Dasynoc, their flagship medicine, has a PDUFA date of October 7, 2025, and is pending FDA approval. Selective consideration may be given to other license agreements.

“The agreement confirms the value of our patent portfolio and demonstrates that our long-term work to build our comprehensive patent portfolio is paying off. As for the dasatinib market, I’m convinced that when Dasynoc is launched it will be seen as the premium product in its market segment as it combines pH-independent absorption with lower dose strength and high precision, eliminating sensitivity to all acid-reducing agents,” says Per Andersson, CEO of Xspray Pharma. Additionally, the agreement guarantees that any U.S. regulatory exclusivities pertaining to Handa's unlaunched product will not affect Xspray's scheduled Dasynoc launch.

Also Read: IIMA and Novo Nordisk Collaborate to Promote Obesity Treatment in India

Xspray Pharma creates better versions of existing protein kinase inhibitors (PKIs), also referred to as original medicines, for the treatment of cancer using its cutting-edge, patented HyNap technology. The oncology market is the biggest, and the cost of medications is very expensive.

When PKIs first hit the market more than 20 years ago, they completely changed the way that cancer was treated. Today, the US market has more than 80 approved PKIs. Notwithstanding their therapeutic benefits, they are linked to issues such poor solubility, significant absorption fluctuation, and effects on uptake when combined with food and other medications.